EMEA-001119-PIP03-19-M02

Table of contents

Key facts

Invented name
  • Kisplyx
  • Lenvima
Active substance
Lenvatinib
Therapeutic area
Oncology
Decision number
P/0154/2022
PIP number
EMEA-001119-PIP03-19-M02
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thyroid cancer, follicular thyroid cancer and osteosarcoma
Route(s) of administration
Oral use
Contact for public enquiries
Eisai GmbH

E-mail: EUMedInfo@eisai.net
Tel.  +44  8456761400

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating